<DOC>
	<DOCNO>NCT00694603</DOCNO>
	<brief_summary>The purpose research study find well cetuximab work treat NSCLC patient previously treat class drug call tyrosine kinase inhibitor ( TKI ) . Cetuximab protein design block substance cancer cell call `` epidermal growth factor receptor '' EGFR . EGFR help cancer cell grow .</brief_summary>
	<brief_title>Cetuximab Therapy Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy</brief_title>
	<detailed_description>- Participants study receive cetuximab infusion intravenously per week may continue receive weekly cetuximab infusion disease progress experience unacceptable side effect . - The following performed every 4 week receive study treatment : Physical examination ; performance status ; blood work . A CT scan chest upper abdomen perform every 8 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathologically confirm stage IIIB IV recurrent progressive NSCLC Patients must progress receive treatment tyrosine kinase inhibitor target EGFR pathway Measurable disease , define RECIST criterion Patients must suitable frozen paraffinembedded tissue sample available EGFR mutational analysis . Prior EGFR mutational analysis allowable Patients asymptomatic brain metastasis eligible ; however , must complete radiotherapy/radiosurgery least 3 week prior enrollment clinically stable ECOG Performance Status 02 18 year age older Negative pregnancy test within 7 day treatment categorize childbearing potential Bone marrow function , renal function , hepatic function outline protocol Women pregnant breastfeed Active concurrent malignancy Major thoracic abdominal surgery within 30 day prior first infusion cetuximab Significant history uncontrolled cardiac disease Uncontrolled seizure disorder , active neurological disease Prior severe infusion reaction monoclonal antibody Prior chemotherapy regimen within 21 day prior study entry Any EGFR tyrosine kinase inhibitor within 14 day study entry Radiation therapy within 14 day prior first infusion cetuximab Acute hepatitis know HIV Active uncontrolled infection Any concurrent chemotherapy investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>